These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7514829)

  • 1. Drugs recently released in Belgium. Eflornithine--finasteride.
    Harvengt C
    Acta Clin Belg; 1994; 49(1):42-6. PubMed ID: 7514829
    [No Abstract]   [Full Text] [Related]  

  • 2. The medication minute: Finasteride.
    Bartek JK
    Urol Nurs; 1994 Mar; 14(1):29-30. PubMed ID: 7512281
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.
    Guess HA; Heyse JF; Gormley GJ; Stoner E; Oesterling JE
    Urol Clin North Am; 1993 Nov; 20(4):627-36. PubMed ID: 7505970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia.
    Stoner E; Guess H
    Aust N Z J Surg; 1995 May; 65(5):360. PubMed ID: 7537957
    [No Abstract]   [Full Text] [Related]  

  • 5. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.
    Peters DH; Sorkin EM
    Drugs; 1993 Jul; 46(1):177-208. PubMed ID: 7691505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Does St. John's wort interact with finasteride?].
    Lochner S; Kirch W
    Dtsch Med Wochenschr; 2011 Aug; 136(34-35):1746. PubMed ID: 21877309
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of men on finasteride.
    Gormley GJ
    Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination drug therapy for benign prostatic hyperplasia.
    Kreder KJ
    JAMA; 1995 Jul; 274(4):359. PubMed ID: 7541871
    [No Abstract]   [Full Text] [Related]  

  • 9. Finasteride, a steroid 5 alpha-reductase inhibitor, does not affect the oxidative metabolism of antipyrine.
    Winchell GA; Gregoire S; Taylor AM; Hegland J; Hunninghake DB
    J Clin Pharmacol; 1993 Oct; 33(10):967-70. PubMed ID: 7693768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride in polycythaemia.
    Viegas S; Malone P; Brito-Babapulle F
    BJU Int; 2003 Dec; 92 Suppl 3():e60. PubMed ID: 19127639
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H; Kanetake H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical pharmacokinetics and pharmacodynamics of finasteride.
    Steiner JF
    Clin Pharmacokinet; 1996 Jan; 30(1):16-27. PubMed ID: 8846625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [5-alpha-reductase inhibitors].
    De Jaegher K; Kozyreff P; Claes H
    Acta Urol Belg; 1994 Dec; 62(4):23-31. PubMed ID: 7540795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug therapy for prostatic hyperplasia].
    Sane T
    Duodecim; 1993; 109(20):1849-54. PubMed ID: 7537654
    [No Abstract]   [Full Text] [Related]  

  • 15. [Finasteride in prolonged therapy of patients with benign prostatic hyperplasia].
    Mazo EB
    Urologiia; 2001; (3):20-2. PubMed ID: 11505535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5alpha-reductase inhibitors/finasteride.
    Stoner E
    Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia.
    Nacey JN; Meffan PJ; Delahunt B
    Aust N Z J Surg; 1995 Jan; 65(1):35-9. PubMed ID: 7529489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of randomized clinical trials of finasteride.
    Roehrborn CG
    Urology; 1998 Apr; 51(4A Suppl):46-9. PubMed ID: 9586596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finasteride, MSD: Innovation in the Management of Benign Prostatic Hyperplasia. Proceedings of a symposium. Seville, Spain, November 3, 1991.
    Eur Urol; 1994; 25 Suppl 1():1-36. PubMed ID: 7507049
    [No Abstract]   [Full Text] [Related]  

  • 20. [Benign prostatic hyperplasia. Finasteride controls progression of BPH].
    MMW Fortschr Med; 2000 Jun; 142(25):62-3. PubMed ID: 10920676
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.